2.

3.
Vaccine review: “ Staphyloccocus aureus vaccines: Problems and prospects”
by Jansen, Kathrin U
Vaccine, 2013, Vol.31 (25), p.2723-2730

4.
Informing vaccine decision-making: A strategic multi-attribute ranking tool for vaccines—SMART Vaccines 2.0
by Knobler, Stacey
Vaccine, 2016, Vol.35, p.A43-A45

5.
Vaccine decision-making begins in pregnancy: Correlation between vaccine concerns, intentions and maternal vaccination with subsequent childhood vaccine uptake
by Danchin, M.H
Vaccine, 2018-10-22, Vol.36 (44), p.6473-6479

6.
Durability of the neutralizing antibody response to vaccine and non-vaccine HPV types 7 years following immunization with either Cervarix® or Gardasil® vaccine
by Godi, Anna
Vaccine, 2019-04-24, Vol.37 (18), p.2455-2462

7.
Non-interference of Bovine-Human reassortant pentavalent rotavirus vaccine ROTASIIL® with the immunogenicity of infant vaccines in comparison with a licensed rotavirus vaccine
by Desai, Sajjad
Vaccine, 2018-09-05, Vol.36 (37), p.5519-5523

8.
Safety surveillance of meningococcal group B vaccine (Bexsero®), Vaccine Adverse Event Reporting System, 2015–2018
by Perez-Vilar, Silvia
Vaccine, 2022-01-21, Vol.40 (2), p.247-254

9.
Trivalent MDCK cell culture-derived influenza vaccine Optaflu® (Novartis Vaccines)
by Doroshenko, Alexander
Expert review of vaccines, 2009-06-01, Vol.8 (6), p.679-688

10.
Early smallpox vaccine manufacturing in the United States: Introduction of the “animal vaccine” in 1870, establishment of “vaccine farms”, and the beginnings of the vaccine industr...
by Esparza, José
Vaccine, 2020-06-19, Vol.38 (30), p.4773-4779

11.

12.
Evidence for single-dose protection by the bivalent HPV vaccine—Review of the Costa Rica HPV vaccine trial and future research studies
by Kreimer, Aimée R
Vaccine, 2018-08-06, Vol.36 (32), p.4774-4782

13.
Is there any harm in administering extra-doses of vaccine to a person? Excess doses of vaccine reported to the Vaccine Adverse Event Reporting System (VAERS), 2007–2017
by Moro, Pedro L
Vaccine, 2019-06-19, Vol.37 (28), p.3730-3734

14.
Antibody persistence after vaccination of adolescents with monovalent and combined acellular pertussis vaccines containing genetically inactivated pertussis toxin: a phase 2/3 rand...
by Pitisuttithum, Punnee
The Lancet infectious diseases, 2018-11, Vol.18 (11), p.1260-1268

15.

16.
Influenza B vaccine lineage selection—An optimized trivalent vaccine
by Mosterín Höpping, Ana
Vaccine, 2016, Vol.34 (13), p.1617-1622

17.
Binding antibody levels to vaccine (HPV6/11/16/18) and non-vaccine (HPV31/33/45/52/58) HPV antigens up to 7 years following immunization with either Cervarix® or Gardasil® vaccine...
by Panwar, Kavita
Vaccine, 2022-02-23, Vol.40 (9), p.1198-1202

18.
Understanding vaccine hesitancy around vaccines and vaccination from a global perspective: A systematic review of published literature, 2007–2012
by Larson, Heidi J
Vaccine, 2014, Vol.32 (19), p.2150-2159

19.
Intussusception after monovalent rotavirus vaccine—United States, Vaccine Adverse Event Reporting System (VAERS), 2008–2014
by Haber, Penina
Vaccine, 2015, Vol.33 (38), p.4873-4877

20.
